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Abstract
Tumors express a wide variety of both mutated and nonmutated Ags. Whether these tumor Ags are
broadly recognized as self or foreign by the immune system is currently unclear. Using an
autochthonous prostate cancer model in which hemagglutinin (HA) is specifically expressed in the
tumor (ProHA × TRAMP mice), as well as an analogous model wherein HA is expressed in
normal tissues as a model self-Ag (C3HAhigh), we examined the transcriptional profile of CD4 T
cells undergoing Ag-specific division. Consistent with our previous data, transfer of Ag-specific
CD4 T cells into C3HAhigh resulted in a functionally inactivated CD4 T cell profile. Conversely,
adoptive transfer of an identical CD4 T cell population into ProHA × TRAMP mice resulted in the
induction of a regulatory phenotype of the T cell (Treg) both at the transcriptional and functional
level. Interestingly, this Treg skewing was a property of even early-stage tumors, suggesting Treg
induction as an important tolerance mechanism during tumor development.
The development of tumors in immunocompetent hosts is generally thought to be
accompanied by the subversion of an effective antitumor immune response (1–4). This
process, known as immune evasion, is multifactorial and includes alterations in Ag
processing, Ag presentation, expression of immune-inhibitory molecules such as TGF-β and
IDO, as well as the expression of cell surface molecules such as B7-H1 that inhibit immune
function (2–8). As a consequence of these and other mechanisms, the T cell response to
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tumors is correspondingly blunted or absent, as evidenced by a lack of lytic function in CD8
T cells and a lack of effector cytokine production by specific CD4 T cells (9–17).
To better understand the nature of this functional CD4 T cell tolerance, we examined the
transcriptional profile of CD4 T cells that recognize nonmutated tumor Ag, using both self-
Ag and viral Ag recognition for comparison. For these studies, we used a well-described
adoptive transfer system in which TCR-transgenic T cells specific for hemagglutinin (HA)4
are introduced into mice expressing their cognate Ag as a self-Ag or as tumor-restricted Ag
(14, 18–21). In the self-Ag system, the C3 promoter drives HA expression in the lung, as
well as in other normal tissues (19). In the tumor system, prostate-specific expression of HA
is driven by the minimal rat probasin promoter (14, 22). These mice are termed ProHA
(Probasin HA). For a tumor model, we utilized the transgenic adenocarcinoma of the mouse
prostate (TRAMP) model, which develops autochthonous prostate tumors in a progressive
manner (22, 23). By intercrossing ProHA with TRAMP mice, we created a murine system in
which a well-defined tumor Ag is expressed in a tumor- and tissue-specific manner (14). In
both ProHA × TRAMP and C3HAhigh mice, CD4 T cell recognition of cognate Ag is
accompanied by division as well as by functional tolerance as evidenced by a lack of
effector cytokine production (20, 24). Our data, involving transcriptional profiling of CD4 T
cells isolated from these distinct models, supports the notion that CD4 T cell recognition in
the context of an evolving prostate tumor results in a phenotype different from that induced
by self-Ag recognition, one characterized by a relative up-regulation of the transcription
factor FoxP3 and the development of a regulatory T cell phenotype.
These data are consistent with previously published studies suggesting that tumors may
specifically expand or induce regulatory T cells and that multiple tumor types are infiltrated
with regulatory T cells (Treg) in humans with cancer (25–32). In addition, our data suggest
that these cells represent induced as opposed to natural Tregs, which arise spontaneously in
the thymus (33–38). Because tumors in TRAMP mice evolve slowly over time, we were
also able to examine the relative effect of tumor stage on Treg induction/expansion by
evaluating the results of adoptive transfer to younger vs older animals (39). Surprisingly,
Treg induction/expansion was a characteristic of even very early precancerous lesions
(prostatic intraepithelial neoplasia, or PIN), suggesting that Treg induction by evolving
tumors might be a relatively early contributor to T cell tolerance (40).
Materials and Methods
Mice
All mice were on the B10.D2 (H-2d) background. C3-HA-transgenic mice express influenza
HA under the control of the C3 promoter and have been previously described (19, 20). The
strain of 6.5 mice are CD4 TCR-transgenic animals that recognize an I-Ed-restricted HA
epitope (110SFERFEIF-PKE120; Ref. 18). These mice were backcrossed to a Thy1.1-
congenic B10.D2 background for >12 generations. TRAMP mice on the C57BL/6J
background were backcrossed to the B10.D2 background for >14 generations (22). ProHA
mice express HA in a prostate-restricted manner under the control of the same minimal rat
probasin promoter used to generate TRAMP mice and have been previously described (14).
ProHA × TRAMP mice were generated by backcrossing ProHA to TRAMP mice for >16
generations (14). Animal care and experimental procedures were performed under pathogen-
free conditions in accordance with established institutional protocols from Institutional
Animal Care and Use Committees of Johns Hopkins University.
4Abbreviations used in this paper: HA, hemagglutinin; TRAMP, transgenic adenocarcinoma of the mouse prostate; PIN, prostatic
intraepithelial neoplasia; Treg, regulatory T cell; VaccHA, Vaccinia-hemagglutinin; LMHA, Listeria monocytogenes-HA; DC,
dendritic cell.
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Adoptive transfer
Donor TCR-transgenic (6.5) mice were sacrificed via CO2 asphyxiation. Spleens and lymph
nodes were collected and homogenized, and RBCs were lysed. CD4 T cells were purified
using Miltenyi magnetically labeled beads according to the manufacturer’s protocol. For
some experiments, purified cells were labeled with for 8 min with CFSE (Invitrogen) by
adding 0.5 μl of 5 mM stock per 1 ml of cells. After labeling, cells were washed twice and
resuspended in HBSS for i.v. injections. Purified cells (5 × 106) were injected per mouse in
0.2 ml total volume by tail vein injection. For CD4 T cell activation controls, nontransgenic
B10.D2 mice were infected with recombinant Vaccinia virus expressing wild-type HA
protein as previously described (14).
Flow cytometry/intracellular staining
Lymph nodes were harvested 3–10 days post-adoptive transfer, and single-cell suspensions
were prepared. RBCs were lysed with ammonium chloride-potassium lysis buffer. All
staining reagents were purchased from Pharmingen, with the exception of FoxP3, which was
analyzed using a prepared kit according to the manufacturer’s instructions (Ebiosciences).
After 10 min of incubation, samples were washed once in PBS plus 1% FBS solution and
analyzed using a FACSCalibur instrument (BD Biosciences). Intracellular cytokine analysis
was performed as previously described (41). Data were analyzed using the FloJo software
package (Treestar).
Direct ex vivo Ag detection
A direct ex vivo Ag detection assay was performed as previously described (42, 43). Briefly,
HA-specific memory cells were generated by adoptive transfer of cells into nontransgenic
B10.D2 recipients that received primary vaccination of Vaccinia-hemagglutinin (VaccHA).
Two weeks after initial transfer; B10.D2 recipient received a secondary boost of Listeria
monocytogenes-HA (LMHA). Two weeks after LMHA boost, all lymph nodes and spleena
were harvested from host mice, and responder CD4 T cells were enriched using anti-Thy1.1-
biotin Ab and streptavidin microbeads (Miltenyi Biotech). class IIhighCD11chigh dendritic
cells (DC) were enriched from the iliac lymph nodes from ProHA × TRAMP, C3HAhigh,
and VaccHA-vaccinated B10.D2 animals as stimulators. Responder CD4 T cells (2 × 104)
were incubated with 1 × 103 stimulators, resulting in a 20:1 ratio of responder to stimulator.
Reactions were set up in triplicates. Forty-eight hours later, cultures were pulsed with 1 μCi
of [3H]TdR and incubated for an additional 24 h before harvest with a Packard Micromate
cell harvester. Determination of the amount of incorporated radioactive counts was
performed with a Packard Matrix 96 direct beta counter (Packard Biosciences).
Donor CD4 T cell isolation
From 3 to 7 days post-adoptive transfer of HA-specific CD4 T cells, recipient animals were
euthanized, and lymph nodes were harvested. CD4+ T cells were enriched by depleting CD8
and B cells using biotinylated anti-CD8, anti-B220, and MACS LS separation columns
(Miltenyi Biotech) as previously described (21). Ag-specific T cells that had undergone
specific division in vivo were sorted using a FACSVantage SE cell sorter (BD Biosciences),
gating on CFSE-diluted, CD4+Thy1.1+ cells. As all recipient animals are of the Thy1.2
phenotype, this technique results in >95% pure donor cells and avoids the use of TCR-
specific or CD4 core-ceptor-specific Abs that could potentially alter TCR- or CD4-
dependent gene expression patterns. Control naive T cells were isolated in a similar manner,
using nontransgenic B10.D2 animals as recipients, but instead of gating on CFSElow cells,
the undivided, CFSEhigh cells were isolated.
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Transcriptional analysis
Sorted cells were pelleted, frozen under 1 ml of Trizol, and stored at −80°C before RNA
extraction using the Trizol reagent. Our microarray experiment was controlled using paired
biological replicates. For these experiments, an identical population of CD4 T cells was
adoptively transferred to the two groups of mice at a time. Then, cells were flow-sorted from
each group of >10 mice separately, and further processing was performed in parallel; i.e.,
sorting, RNA extraction, template preparation, and analysis were done in parallel, using two
separate Affymetrix chips. The integrity of extracted RNA from T cells was analyzed using
an Agilent 2100 bioanalyzer and the RNA 6000 Pico and Nano Kits (Agilent Technologies),
and concentrations were determined using a NanoDrop spectrophotometer (NanoDrop
Technologies). Transcriptional analysis was performed at the Johns Hopkins Microarray
Core facility. Per the standard protocol, RNA was amplified from 20 ng of starting total
RNA with the Nugen Ovation RNA Amplification System V2, following the manufacturer’s
protocol (http://www.nugeninc.com/pdfs/ov-v2_userguide.pdf). cDNA was synthesized
using the Nugen FL-Ovation cDNA Biotin Module V2 kit, following the manufacturer’s
protocol (http://www.nugeninc.com/pdfs/flbv2_userguide.pdf). After standard labeling, each
sample was hybridized to an Affymetrix Mouse 430 Plus2 expression array, followed by
interrogation with an Affymetrix GeneChip Scanner 3000. RMA analysis of paired
replicates revealed a striking concordance, with fewer than 300 of 36,000 transcripts
different at the p < 0.05 level.
Statistical analysis
To estimate the gene expression signals, data analysis was conducted on the CEL file probe
signal values of the chip at the Affymetrix probe pair (perfect match probe and mismatch
probe) level, using the statistical algorithm robust multiarray average expression measure
(44) with Affy. This probe level data processing includes a normalization procedure using a
quantile normalization method to reduce the obscuring variation between microarrays,
which might be introduced during the processes of sample preparation, manufacture,
fluorescence labeling, hybridization, and/or scanning (45). Using the signal intensities
estimated above, an empirical bias method with the γ- γ modeling, as implemented in the
bioconductor package EBarrays, was used to estimate the posterior probabilities of the
differential expression of genes between the sample conditions. The criterion of the posterior
probability >0.5, which means the posterior odds favoring change, was used to produce a
differentially expressed gene list. Heatmaps were created using TreeView package version
1.60 (46).
Quantitative PCR
Quantitative PCR was performed as previously described (21). Briefly, RNA was
immediately extracted from sorted 6.5 CD4+ T cells using the Trizol reagent (Invitrogen).
Reverse transcription was performed with the Superscript First Strand Synthesis System
(Invitrogen). cDNA levels were analyzed by real-time quantitative PCR with the TaqMan
system (Applied Biosystems). Each sample was assayed in triplicates for the target gene
together with 18S rRNA as the internal reference in a 25-μl final reaction volume, using the
TaqMan Universal PCR Master Mix and the ABI Prism 7700 Sequence Detection system.
The relative mRNA frequency was determined by normalization to the internal control 18S
RNA. Relative mRNA frequencies were calculated as 2ΔΔCt, where ΔΔCt = (ΔCt calibration −
ΔCt sample).
Suppression assay
In vitro suppression assays were performed as previously described (34). Briefly, 1 × 104
purified T cells (responders) were mixed with 1 × 103 6.5 CD4+ T cells sorted from various
Getnet et al. Page 4
J Immunol. Author manuscript; available in PMC 2011 April 26.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
recipients (suppressors), giving a 1:10 suppressor-to-responder ratio. Cells were then
incubated in flat-bottom 96-well tissue culture plates precoated with 5 μg/ml anti-CD3e in
200 μl of CTL media. After 72 h, cultures were pulsed with 1 μCi of [3H]TdR and incubated
for an additional 16 h before harvest with a Packard Micromate cell harvester.
Determination of the amount of incorporated radioactive counts was performed with a
Packard Matrix 96 direct beta counter (Packard Biosciences).
Immunohistochemistry
For immunohistochemistry, dorsal lobes of the prostate were harvested from a 6-, 10-, and
24-wk-old ProHA × TRAMP animals and frozen in Sakura Tissue-tek OCT compound
(Accurate Chemical and Scientific) as described by the manufacturer. Serial unstained
sections from the dorsal prostate lobes were then cut. Unstained slides were fixed in 75%
acetone, 25% ethanol for 5 min. Dry slides were washed three times in PBS, followed by a
30-min incubation with Image-iT FX signal enhancer (Molecular Probes). Slides were
washed in PBS, blocked with serum, washed, and incubated with polyclonal rabbit Ki67
(Abcam) for 45 min. Slides were washed and incubated with anti-rabbit IgG HRP for 30
min. Diaminobenzidine was used as the chromogen. Slides were then imaged on a
microscope.
In vivo Ab blocking
For in vivo TGF-β blocking experiments, ProHA × TRAMP and control B10.d2 mice were
injected with 0.2 mg of anti-TGF-β (2G7 or 1D11) Ab (R&D Systems) or the control IgG
(Jackson ImmunoResearch Laboratories) at the time of adoptive transfer of naive transgenic
T cells with a second dose administered 3 days later. As above, mice were harvested 5–10
days post-adoptive T cell transfer, and T cells were analyzed as described above.
Results
Specific CD4 T cell proliferation to self, viral, and tumor Ag
Previously, we demonstrated that adoptive transfer of HA-specific CD4 clonotypic cells into
C3HAhigh-transgenic mice, in which there is widespread expression of the HA Ag (self Ag
model), generates functionally tolerized T cells that are prone to deletion (19, 20). These
CD4 T cells are characterized by a lack of IFN-γ or IL-2 secretion upon restimulation ex
vivo. Similarly, adoptive transfer of identical HA-specific CD4 T cells to animals in which
HA is expressed as a prostate/prostate cancer-restricted Ag also results in functional
tolerance (14). To assess whether the proliferative response to a self Ag or tumor Ag was
broadly comparable in these two models, naive HA-specific CD4 T cells were CFSE labeled
and transferred into the following recipients: 1) no Ag (B10.D2); 2) viral Ag (VaccHA); 3)
self Ag (C3HAhigh); and 4) prostate tissue/tumor Ag (ProHA × TRAMP; Fig. 1A).
Adoptively transferred HA-specific CD4 T cells proliferated robustly in response to
recognition of self or viral Ag. However, proliferation in response to the prostate/prostate
cancer-restricted Ag was less robust and was primarily restricted to the prostate-draining
(iliac) lymph nodes (14). Additionally, proliferation in single-transgenic ProHA mice is
barely detectable under these conditions (data not shown), consistent with the notion that
tumorigenesis is required for Ag recognition in this model (14).
We next sought to determine whether DCs were capable of driving HA-specific CD4
proliferation by performing a direct ex vivo Ag detection (DEAD) assay (42, 43). Memory
HA-specific CD4 T cells were generated by adoptively transferring cells into B10.D2
(nontransgenic) hosts with a primary immunization of VaccHA and boosted with LMHA.
Four weeks after initial transfer, memory CD4 T cells were enriched from vaccinated hosts
using Thy1.1 microbeads and incubated with CD11chigh DCs isolated from the lymph nodes
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of various experimental animals. As a positive control, DCs were isolated from the lymph
nodes of VaccHA-infected nontransgenic mice. DCs isolated from single-transgenic ProHA
and TRAMP (without HA) mice were used as negative controls given that the proliferation
of HA-specific clonotypic cells is minimal following adoptive transfer. DCs from the lymph
nodes of both tumor- and self Ag-bearing animals were capable of driving significant (p <
0.05) proliferation of memory HA-specific CD4+ T cells, confirming similar reports that HA
is cross-presented in the C3HAhigh self Ag model and demonstrating DC as a likely APC in
the ProHA × TRAMP model (Refs. 19 and 47 and Fig. 1B).
Transcriptional analysis of CD4 T cells specific for tumor or self Ag
We next sought to determine whether these various Ag-specific proliferative stimuli would
result in distinct transcriptional profiles in vivo. Naive, CFSE-labeled, Thy1.1+ HA-specific
CD4 T cells were adoptively transferred into nontransgenic (no Ag), VaccHA-vaccinated
(viral Ag), C3HAhigh (self-Ag), and ProHA × TRAMP (tumor/tissue Ag) recipients. As
shown in Fig. 1A, Thy1.1+ CFSE diluted clonotypic cells were FACS sorted from VaccHA,
C3HAhigh, and ProHA × TRAMP recipients, whereas CFSE undiluted cells from
nontrangenic recipients were sorted as a negative control for the adoptive transfer and
isolation procedures. Transcriptional profiles were determined using the Affymetrix 430A
GeneChip microarray representing 39,700 transcripts and analyzed using the statistical
criteria previously described (48). Compared with naive cells isolated from nontransgenic
controls, microarray analysis revealed 3908 transcripts differentially expressed during viral
Ag recognition, 5479 transcripts in self Ag recognition, and 3572 differentially expressed
transcripts in tumor Ag recognition (Fig. 2 and supplemental Tables I–III).5 Only 780
unique transcripts were significantly differentially expressed between CFSE diluted tumor
vs self Ag recognizing CD4 T cells. A curated list of the top 40 up-regulated (Fig. 2A) and
down-regulated (Fig. 2B) genes involved in tumor vs self Ag recognition is presented in
Tables I and II. These genes represent a broad array of molecules, including transcription
factors such as FoxP3, Madh1, and Znfn1a2; anti-apoptosis molecules such as Bcl2 and
Bcl-11b; signaling molecules; and cell surface markers. A similar comparison revealed 1930
transcripts that were differentially expressed in tumor Ag-recognizing CD4 T cells as
compared with viral-associated Ag-recognizing T cells (Table III and IV). Overall, these
data appear to be consistent with previously published data from our group and others (21,
37, 49, 50). Among many others, we noted the expected up-regulation of IFN-γ in CD4 T
cells recognizing HA in the context of viral infection, and a relative up-regulation of the T
cell surface protein LAG-3 in the self-tolerance (C3HAhigh) model (21).
CD4 T cells that recognized tumor-associated Ag have a Treg phenotype
In the set of transcripts up-regulated in response to tumor-recognition, we noted the
transcription factor FoxP3, a relatively well-established marker of regulatory T cell (Treg)
(33, 34, 51–53). To verify these data, we performed quantitative PCR analysis on CFSE-
diluted HA-specific CD4+ T cells isolated after adoptive transfer. As shown in Fig. 3A, CD4
T cells isolated from ProHA × TRAMP tumor-bearing animals expressed significantly
higher FoxP3 mRNA levels than cells harvested from C3HAhigh or Vacc-HA-infected
nontransgenic mice (p < 0.05). We next tested whether these transcriptional changes were
reflected at the protein level by intracellular staining for FoxP3 (Fig. 3B), and found the
expected up-regulation. Tregs may be functionally distinguished from other T cell subsets
by their capacity to suppress the proliferative response of activated T cells (54). Thus, we
next sought to determine whether these tumor-induced Tregs were capable of suppressing
proliferation of responder cells using an in vitro suppression assay. For these studies, anti-
5The online version of this article contains supplemental material.
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CD3-activated T cells from nontransgenic mice were used as responders. Naturally
occurring CD4+ CD25+ T cells were FACS sorted as control suppressors from the same
mice that were the source for responders. FACS-sorted HA-specific CD4 T cells from
ProHA × TRAMP recipients were able to suppress the proliferation of responders in a
manner similar to that of natural Tregs (Fig. 3C). In accordance with our previously
published data, Ag-experienced CD4 T cells isolated from self Ag-expressing animals were
also able to suppress to some degree in this assay, despite a lack of relative overexpression
of FoxP3 (21). These data are in agreement with multiple reports suggesting that FoxP3
expression is not an absolute requirement for suppressive activity in vitro (55).
Treg development is an early event in ProHA × TRAMP animals
In the same manner as TRAMP mice, ProHA × TRAMP mice reliably develop
autochthonous prostate tumors in an age-dependent manner (39). In young mice, typically
<6 wk, the prostate glands appear grossly normal (Fig. 4A). Between 6 and 10 wk,
hyperplasia and cribriform structures appear, a lesion that has been termed murine PIN (39).
Finally, older animals develop overtly neoplastic lesions, with metastatic spread to the
draining lymph nodes and liver. We took advantage of the progressive nature of this model
to query whether Treg development was a function of tumor stage. Naive CFSE-labeled,
HA-specific CD4+ T cells were adoptively transferred to ProHA × TRAMP mice of various
ages, harvested from the prostate-draining lymph nodes, and evaluated for FoxP3 expression
by intracellular staining. Divided cells appeared to up-regulate FoxP3 even in mice in which
tumor development was not obvious on gross pathological examination (Fig. 4B). These
data suggest that induction of Treg might be a relatively early event in tumor development.
Glucocorticoid-induced TNFR family-related gene staining did not correlate with the
FoxP3-stained population in our system.
Although CFSE labeling experiments (Fig. 4B) suggested that the Tregs observed in this
model represent induced Tregs, rather than the expansion of natural CD4+ CD25+ Tregs, we
attempted to address this issue more completely by depleting donor T cells of CD25+ T cells
before adoptive transfer using FACS sorting. As shown (Fig. 4C), this process was
reasonably efficient, the CD25low CD4 fraction was <1% FoxP3+, as opposed to the
CD25high CD4 fraction, which was 95% FoxP3+. These CD4+CD25low-sorted Thy1.1+ HA-
specific T cells were adoptively transferred to ProHA × TRAMP mice and recovered from
the tumor-draining iliac lymph nodes 10 days posttransfer. By this time point, >15% of these
HA-specific cells were FoxP3+ by intracellular staining, supporting the hypothesis that
tumor recognition may induce specific Tregs in vivo. Finally, we attempted to investigate a
potential role for TGF-β in the development of Tregs in this system, by administering TGF-β
blocking mAb (2G7) during and after adoptive transfer of HA-specific CD4 T cells into
ProHA × TRAMP mice and naive B10.d2 hosts. As shown in Fig. 4D, blocking TGF-β in
vivo did not significantly affect the percentage of FoxP3+ Thy1.1 cells compared with
control IgG group. Similar results were obtained using a second TGF-β blocking mAb 1D11
(data not shown).
Discussion
In these studies, we used well-established tolerance models to study the transcriptional
profiles of CD4 T cells responding to either tumor Ag or self Ag recognition in vivo. For a
tumor model, we used TRAMP-transgenic mice (22). These mice develop PIN during
puberty followed by a progressive invasive carcinoma and metastasis of epithelial origin in
the adult male animals (56). For our studies, TRAMP mice were crossed with our ProHA
mice that express influenza HA under the control of the identical probasin promoter used in
TRAMP mice (14). Thus, in ProHA × TRAMP mice, expression of the nonmutated tumor
Ag HA is a function of tumor progression. C3HAhigh-transgenic mice were developed to
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study T cell tolerance to self-Ag; in these animals HA is widely expressed under the control
of the rat C3 promoter (19, 20). We found that both self and tumor recognition resulted in
relative up-regulation and down-regulation of large numbers of transcripts as compared with
naive cells, but that a number of genes appeared to be differentially expressed between the
two conditions. These data generally suggest that tumor and self-recognition result in
different CD4 T cell profiles, but this interpretation must be tempered by several other
differences between the two models, including a more robust division in the self Ag model,
and the far more localized nature of Ag in the ProHA × TRAMP model.
Our transcriptional data also suggested a significant up-regulation of FoxP3 in tumor vs self-
tolerance. This was somewhat surprising because our transcriptional profiling studies were
designed in an open-ended manner, evaluating tens of thousands of transcripts in parallel
without a specific hypothesis regarding the gene sets that would be found. Up-regulation of
FoxP3 was confirmed at both the transcriptional level and at the protein level, and correlated
with a suppressive phenotype in the in vitro suppression assay (Fig. 3C). These data are
consistent with multiple reports of tumor-induced Tregs, by our group and others (27, 57,
58). Tumors may not be unique in their ability to induce or expand Tregs from a naive CD4
T cell population, as the Von Boehmer group has reported generation of regulatory T cells to
both ubiquitously expressed Ag and low-level Ag encountered chronically (59–61).
Several other groups have reported a transcriptional profile for Tregs using in vivo models
(37, 49, 50). Our data are somewhat unique in this respect, given that we did not initially set
out with the goal of profiling Tregs. However, our data appear to be broadly consistent with
prior work. For example, both Sakaguchi’s group (49)and Rudensky’s group (37) found up-
regulation of ZFN1a2 in natural Tregs, and here we report a similar up-regulation. Similarly,
all three studies report up-regulation of Nrp, ZFN1a4, CD86, Myb, CTL4, and BCL2 family
members. However, our dataset also includes a number of unique transcripts that were
previously not associated with Tregs such as CD83, Madh1, Infra2, and Scy1. Our complete
transcriptional dataset is deposited in the Geo database at the National Center for
Biotechnology Information (accession number GSE14662; www.ncbi.nlm.nih.gov/geo/); in-
depth examination of these profiles using pathway or comparative assays could conceivably
provide additional insight into the biochemical pathways involved in Treg induction and
function.
Previous studies in TRAMP mice and their derivatives demonstrated T cell tolerance to
prostate-associated Ag(s), with several of these reports suggesting an age dependence to this
mechanism (9, 16, 62– 65). However, the relationship between Tregs and T cell tolerance in
the TRAMP model is less clear, as at least one study reported that Treg depletion in these
animals did not affect the vaccine response in vivo (47, 62). Our data provide additional
insight into this issue, suggesting that the ability to induce and/or expand Tregs might occur
when tumors are barely pathologically recognizable. These data are also consistent with
recent data presented by the Blankenstein group, who used a spontaneous transgenic tumor
model to show that early recognition of evolving tumors was a critical event in later tumor
tolerance (40, 66). Our findings in this regard have potential clinical relevance as well,
confirming other work highlighting a potential role for Treg depletion in tumor
immunotherapy (67–70).
Several aspects of these data suggest that the Tregs we observe here represent induced Tregs
rather than the expansion of naturally occurring CD4+CD25+ Tregs. First, we observe
FoxP3 expression at the protein level in Ag-specific CD4 T cells that have divided in
response to tumor recognition, but not in undivided (CF-SEhigh) cells (Fig. 4B). These data
are not consistent with those of Valzasina et al. (58), who showed that up-regulation of
FoxP3 is independent of division of tumor Ag-experienced CD4 T cells. These differences
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may reflect differences in TCR affinity or Ag expression in the two systems. We attempted
to address this question more fully by transferring naive CD4 T cells that were sorted to be
CD25low; only a very small fraction (<1%) of such cells are FoxP3+ at the time of transfer.
Posttransfer, these cells showed FoxP3 expression in tumor-draining lymph nodes,
consistent with possible Treg induction. We are cognizant, however, that such studies are
not definitive and that it is certainly possible that these FoxP3 cells represent the result of a
substantial expansion of a small population of natural Tregs in the adoptively transferred
population. To investigate this more fully will require crossing FoxP3-GFP mice into the 6.5
TCR B10.D2-transgenic background animals, such that only cells that are truly FoxP3− can
be definitively sorted out before adoptive transfer.
In summary, we report here the comparative expression profile of Ag-specific CD4 T cells
that have divided in response to tumor Ag, self Ag, and viral Ag. Although these profiles are
interesting in and of themselves, our data demonstrate the induction and/or expansion of
Tregs by tumor recognition, as evidenced by FoxP3 up-regulation at both the transcriptional
and protein levels, as well as the acquisition of a regulatory phenotype in vitro. Ag-
experienced CD4 T cells both from the self or tumor Ag models suppressed proliferating
responder cells, suggesting that the Treg skewing of CD4 T cells is a tumor recognition
phenomenon, whereas the ability to suppress is a shared phenomenon between the two
models. The observation of a relative skewing of Tregs at a very early stage of disease
further supports the notion that the expansion and/or induction of the Treg is a tumor-related
event, a result with clear clinical implications. The Tregs in this system appear to represent
an induced population, although far more extensive studies will be required to address that
particular point more directly. Nevertheless, the transcriptional profile of these cells appears
to be unique, and evaluation of particular transcripts or pathways could conceivably provide
additional therapeutic targets to potentiate an antitumor immune response. Finally, this study
provides evidence that tumor Ag recognition results in a distinct transcriptional profile in
CD4 T cells that is unique from that induced by self Ag recognition.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FIGURE 1.
Ag-specific proliferation of HA-specific CD4 T cells. A, CFSE-labeled HA-specific
Thy1.1+CD4+ T cells were adoptively transferred into recipients presenting HA Ag in
varying contexts; nontransgenic, no Ag; VaccHA, viral Ag; C3HAhigh, self Ag; and ProHA
× TRAMP, tumor Ag. Flow cytometric analysis of Ag-driven CFSE dilution gated on donor
(Thy1.1+) CD4+ T cells. B, Ag presentation assayed using a direct ex vivo ag detection
assay. HA-specific memory CD4 T cells generated from VaccHA-vaccinated recipient mice
were incubated with CD11c+-enriched DCs from the iliac lymph nodes of the indicated
groups. *, p < 0.05 by two-sided Student’s t test; **, p < 0.01.
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FIGURE 2.
Gene expression profiling of Ag-specific CD4 T cells. Gene expression profiling was
performed on pooled FACS-sorted, CFSE-diluted, HA-specific Thy1.1+CD4+ T cells from
the lymph nodes of no Ag (nontransgenic; NT), viral Ag (VaccHA), self Ag (C3HAhigh), or
tumor (ProHA × TRAMP) Ag recognition models using Affymetrix Mouse 430 Plus2.
Differentially expressed genes were identified by comparing the expression profile of the
indicated group to the control group in a pairwise analysis. The top 40 up-regulated (fold
change >4) or down-regulated (fold change <–2) genes were selected from each comparison
pair to generate the heatmap. N, Number of genes statistically different between indicated
groups.
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FIGURE 3.
FoxP3 expression in clonotypic CD4 T cells that recognize tumor-restricted Ag. CFSE-
labeled HA-specific Thy1.1+ CD4+ T cells were adoptively transferred into the indicated Ag
recognition models. CSFE-diluted Thy1.1+ CD4+ T cell were FACS sorted on day 3 from
recipient mice. A, FoxP3 mRNA expression as determined by real-time PCR. B, Intracellular
staining for FoxP3. C, CSFE-diluted CD4 T cells from a tumor Ag recognition model were
able to suppress proliferation of activated responders. An in vitro suppression assay was
performed by FACS sorting CFSE-diluted Thy1.1+ CD4+ T cells from C3HAhigh and
ProHA × TRAMP recipients. Sorted suppressors were coincubated at a 1:10 ratio with 105 T
cell responders activated by anti-CD3-coated plate for 72 h. Proliferation was measured by
[3H]TdR incorporation during the final 18 h of incubation. A p value of <0.05 is denoted by
a single asterisk (*) for statistical significance.
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FIGURE 4.
Treg phenotype in tumor Ag-experienced CD4 T cells. A, Ki67 immunohistochemistry
staining on prostate dorsal lob sections of different age group ProHA × TRAMP animals
indicating pathological progression prostate cancer. B, FoxP3 intracellular staining on
CFSE-labeled HA-specific Thy1.1+CD4+ T cells that were adoptively transferred into the
tumor Ag recognition model (ProHA × TRAMP recipients) at various stages of disease; 6
wk with no apparent disease pathology, 10 wk with low-disease-grade pathology, and 24 wk
with high-disease-grade pathology. C, Apparent de novo FoxP3 expression in HA-specific
Thy1.1+CD4+CD25− T cells adoptively transferred into ProHA × TRAMP mice. D, In vivo
TGF-β blocking with 2G7 in ProHA × TRAMP and B10.d2 hosts did not affect the
frequency FoxP3+ T cells in the iliac lymph node (LN).
Getnet et al. Page 17
J Immunol. Author manuscript; available in PMC 2011 April 26.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Getnet et al. Page 18
Ta
bl
e 
I
G
en
es
 d
iff
er
en
tia
lly
 u
p-
re
gu
la
te
d 
by
 C
D
4 
T 
ce
lls
 e
xp
er
ie
nc
in
g 
A
g 
de
riv
ed
 fr
om
 tu
m
or
 (P
ro
H
A
 ×
 T
R
A
M
P)
 o
r s
el
f (
C
3H
A
hi
gh
)
Pr
ob
e 
Se
t I
D
a
G
en
e 
Sy
m
bo
l
G
en
e 
T
itl
e
Pr
oH
A
 ×
 T
R
A
M
P
C
3-
H
A
Fo
ld
 C
ha
ng
e
14
17
40
9_
at
Ju
n
Ju
n 
on
co
ge
ne
80
9
38
21
.5
14
53
84
0_
at
Pa
bp
c1
Po
ly
(A
)b
-b
in
di
ng
 p
ro
te
in
, c
yt
op
la
sm
ic
 1
10
75
83
13
.0
14
55
80
5_
x_
at
Fo
xP
3
Fo
rk
he
ad
 b
ox
 P
3
34
0
32
10
.5
14
36
22
2_
at
G
as
5
G
ro
w
th
 a
rr
es
t-s
pe
ci
fic
 5
35
7
37
9.
8
14
40
16
9_
x_
at
Ifn
ar
2
IF
N
 (α
 a
nd
 β)
 re
ce
pt
or
 2
49
7
55
9.
0
14
56
95
6_
at
Zf
n1
a2
Zi
nc
 fi
ng
er
 p
ro
te
in
, s
ub
fa
m
ily
 1
A
, 2
85
9
10
3
8.
4
14
39
03
6_
a_
at
At
p1
b1
A
TP
as
e,
 N
a 
+ /
K
 +
-tr
an
sp
or
tin
g,
 β1
 p
ol
yp
ep
tid
e
12
5
15
8.
1
14
48
20
8_
at
M
ad
h1
M
A
D
 h
om
ol
og
 1
20
6
26
7.
8
14
27
27
5_
at
Sm
c4
I1
SM
C
4 
st
ru
ct
ur
al
 m
ai
nt
en
an
ce
 o
f c
hr
om
os
om
es
 4
-li
ke
 1
12
90
18
6
7.
0
14
40
77
0_
at
Bc
l2
B
 c
el
l l
eu
ke
m
ia
/ly
m
ph
om
a 
2
68
6
10
0
6.
9
14
38
94
1_
x_
at
Am
pd
2
A
M
P 
de
am
in
as
e 
2
72
2
10
5
6.
9
14
50
33
9_
a_
at
Bc
l1
1b
B
 c
el
l l
eu
ke
m
ia
/ly
m
ph
om
a 
11
B
25
29
36
9
6.
9
14
41
92
6_
x_
at
Tm
ie
Tr
an
sm
em
br
an
e 
in
ne
r e
ar
70
5
10
7
6.
6
14
37
16
3_
x_
at
G
tf2
h4
G
en
er
al
 tr
an
sc
rip
tio
n 
fa
ct
or
 II
 H
, p
ol
yp
ep
tid
e 
4
31
2
48
6.
5
14
17
67
9_
at
G
fi1
G
ro
w
th
 fa
ct
or
-in
de
pe
nd
en
t 1
85
5
13
5
6.
3
14
28
46
3_
a_
at
Pp
p2
r5
e
Pr
ot
ei
n 
ph
os
ph
at
as
e 
2,
 re
gu
la
to
ry
 su
bu
ni
t B
 (B
56
), 
ε i
so
fo
rm
12
8
20
6.
3
14
40
10
4_
at
Ra
nb
p2
R
A
N
-b
in
di
ng
 p
ro
te
in
 2
67
4
10
7
6.
3
14
40
83
7_
at
H
2-
O
b
H
is
to
co
m
pa
tib
ili
ty
 2
, O
 re
gi
on
 β 
lo
cu
s
21
9
35
6.
3
14
36
80
4_
s_
at
Sc
yl
1
SC
Y
1-
lik
e 
1
25
0
40
6.
3
14
19
81
0_
x_
at
G
li
G
LI
-K
ru
pp
el
 fa
m
ily
 m
em
be
r G
LI
13
92
22
7
6.
1
14
34
89
5_
s_
at
Pp
p1
r1
3b
Pr
ot
ei
n 
ph
os
ph
at
as
e 
1,
 re
gu
la
to
ry
 (i
nh
ib
ito
r)
 su
bu
ni
t 1
3B
72
0
11
8
6.
1
14
48
32
5_
at
M
yd
11
6
M
ye
lo
id
 d
iff
er
en
tia
tio
n 
pr
im
ar
y 
re
sp
on
se
 g
en
e 
11
6
22
04
36
3
6.
1
14
50
09
5_
a_
at
Ac
yp
1
A
cy
lp
ho
sp
ha
ta
se
 1
, e
ry
th
ro
cy
te
 (c
om
m
on
) t
yp
e
13
3
22
6.
0
14
56
46
7_
s_
at
N
ik
N
em
o-
lik
e 
ki
na
se
31
4
53
5.
9
14
48
47
1_
a_
at
Tp
bp
b
Tr
op
ho
bl
as
t-s
pe
ci
fic
 p
ro
te
in
 β
73
7
12
5
5.
9
14
37
82
8_
s_
at
Bi
ng
4
B
IN
G
4 
pr
ot
ei
n
41
5
71
5.
9
14
27
18
6_
a_
at
M
ef
2a
M
yo
cy
te
 e
nh
an
ce
r f
ac
to
r 2
A
18
7
32
5.
9
14
25
51
4_
at
Pi
k3
r1
PI
3K
, r
eg
ul
at
or
y 
su
bu
ni
t, 
po
ly
pe
pt
id
e 
1
15
6
27
5.
7
J Immunol. Author manuscript; available in PMC 2011 April 26.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Getnet et al. Page 19
Pr
ob
e 
Se
t I
D
a
G
en
e 
Sy
m
bo
l
G
en
e 
T
itl
e
Pr
oH
A
 ×
 T
R
A
M
P
C
3-
H
A
Fo
ld
 C
ha
ng
e
14
39
76
8_
x_
at
Se
m
a4
f
Se
m
a 
do
m
ai
n,
 Ig
 d
om
ai
n,
 T
M
 d
om
ai
n,
 a
nd
 sh
or
t c
yt
op
la
sm
ic
 d
om
ai
n
41
9
74
5.
7
14
38
25
9_
at
St
rn
3
St
ria
tin
, c
al
m
od
ul
in
-b
in
di
ng
 p
ro
te
in
 3
32
8
58
5.
6
14
17
73
4_
at
N
ak
ap
95
N
ei
gh
bo
r o
f A
 k
in
as
e-
an
ch
or
in
g 
pr
ot
ei
n 
95
89
1
16
0
5.
6
14
39
44
0_
x_
at
Pt
k 
9I
Pr
ot
ei
n 
ty
ro
si
ne
 k
in
as
e 
9-
lik
e
13
44
24
6
5.
5
14
37
66
7_
a_
at
Ba
ch
2
B
TB
 a
nd
 C
N
C
 h
om
ol
og
y 
2
12
91
23
7
5.
4
14
34
39
9_
at
G
al
nt
6
U
D
P-
N
-a
ce
ty
l-α
-D
-g
al
ac
to
sa
m
in
e:
po
ly
pe
pt
id
e 
N
-a
ce
ty
lg
al
ac
to
sa
m
in
yl
tra
ns
fe
ra
se
 6
15
16
27
8
5.
4
14
40
88
5_
at
Ev
l
En
a-
va
so
di
la
to
r-
st
im
ul
at
ed
 p
ho
sp
ho
pr
ot
ei
n
90
9
16
8
5.
4
14
47
75
7_
x_
at
In
pp
5f
In
os
ito
l p
ol
yp
ho
sp
ha
te
-5
-p
ho
sp
ha
ta
se
 F
18
0
34
5.
3
14
18
64
3_
at
Tm
4s
f1
3
Tr
an
sm
em
br
an
e 
4 
su
pe
rf
am
ily
 m
em
be
r 1
3
53
32
10
04
5.
3
14
36
98
3_
at
C
re
bb
p
C
R
EB
-b
in
di
ng
 p
ro
te
in
67
3
12
7
5.
3
14
30
35
7_
at
H
3f
3b
H
3 
hi
st
on
e,
 fa
m
ily
 3
B
52
7
10
0
5.
3
14
38
21
1_
s_
at
D
bp
D
 si
te
 a
lb
um
in
 p
ro
m
ot
er
-b
in
di
ng
 p
ro
te
in
38
2
73
5.
2
a I
D
, i
de
nt
ifi
ca
tio
n 
nu
m
be
r; 
po
ly
(A
), 
po
ly
ad
en
yl
at
e;
 R
A
N
, R
as
-r
el
at
ed
 n
uc
le
ar
 p
ro
te
in
; G
LI
, g
lio
ta
ct
in
; s
em
a,
 se
m
ap
ho
rin
; T
M
, t
ra
ns
m
em
br
an
e;
 B
TB
, b
ric
-a
-b
ra
c,
 tr
am
tra
ck
, a
nd
 b
ro
ad
 c
om
pl
ex
; C
N
C
,
ca
na
ry
 c
om
pl
ex
; E
na
, e
na
bl
ed
.
J Immunol. Author manuscript; available in PMC 2011 April 26.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Getnet et al. Page 20
Ta
bl
e 
II
G
en
es
 d
iff
er
en
tia
lly
 d
ow
n-
re
gu
la
te
d 
by
 C
D
4 
T 
ce
lls
 e
xp
er
ie
nc
in
g 
A
g 
de
riv
ed
 fr
om
 tu
m
or
 (P
ro
H
A
 ×
 T
R
A
M
P)
 o
r s
el
f (
C
3H
A
hi
gh
)
Pr
ob
e 
Se
t I
D
a
G
en
e 
Sy
m
bo
l
G
en
e 
T
itl
e
Pr
oH
A
 ×
 T
R
A
M
P
C
3-
H
A
Fo
ld
 C
ha
ng
e
14
21
37
5_
a_
at
S1
00
a6
S1
00
 c
al
ci
um
-b
in
di
ng
 p
ro
te
in
 A
6
73
.7
68
3.
6
−9
.3
14
24
54
2_
at
S1
00
a4
S1
00
 c
al
ci
um
-b
in
di
ng
 p
ro
te
in
 A
4
31
.0
26
7.
8
−8
.6
14
49
91
1_
at
La
g3
Ly
m
ph
oc
yt
e 
ac
tiv
at
io
n 
ge
ne
 3
48
.6
39
1.
3
−8
.1
14
22
55
7_
s_
at
M
t1
M
et
al
lo
th
io
ne
in
 1
91
.8
73
9.
2
−8
.1
14
36
16
4_
at
Sl
c3
0a
1
So
lu
te
 c
ar
rie
r f
am
ily
 3
0 
(z
in
c 
tra
ns
po
rte
r)
, m
em
be
r 1
13
7.
8
10
55
.9
−7
.7
14
28
94
2_
at
M
t2
M
et
al
lo
th
io
ne
in
 2
20
9.
4
11
75
.5
−5
.6
14
47
84
9_
s_
at
M
af
A
vi
an
 m
us
cu
lo
ap
on
eu
ro
tic
 fi
br
os
ar
co
m
a 
(v
-m
af
) A
S4
2 
on
co
ge
ne
 h
om
ol
og
19
.4
10
8.
4
−5
.6
14
16
52
9_
at
Em
p1
Ep
ith
el
ia
l m
em
br
an
e 
pr
ot
ei
n 
1
12
.6
59
.5
−4
.7
14
20
11
9_
s_
at
Ph
f3
PH
D
 fi
ng
er
 p
ro
te
in
 3
19
.0
87
.8
−4
.6
14
18
62
2_
at
Ra
b2
R
A
B
2,
 m
em
be
r R
A
S 
on
co
ge
ne
 fa
m
ily
24
.0
10
5.
0
−4
.4
14
55
09
0_
at
An
gp
tl2
A
ng
io
po
ie
tin
-li
ke
 2
15
6.
6
67
2.
9
−4
.3
14
53
22
8_
at
St
x1
1
Sy
nt
ax
in
 1
1
11
4.
6
48
3.
7
−4
.2
14
33
64
8_
at
Sp
ag
9
Sp
er
m
-a
ss
oc
ia
te
d 
A
g 
9
12
7.
0
50
1.
0
−3
.9
14
55
43
9_
a_
at
Lg
al
s1
Le
ct
in
, g
al
ac
to
se
 b
in
di
ng
, s
ol
ub
le
 1
74
3.
7
29
15
.4
−3
.9
14
19
76
1_
a_
at
G
ab
pb
1
G
A
 re
pe
at
 b
in
di
ng
 p
ro
te
in
, β
1
47
.8
18
3.
4
−3
.8
14
18
40
1_
a_
at
D
us
p1
6
D
ua
l-s
pe
ci
fic
ity
 p
ho
sp
ha
ta
se
 1
6
30
.2
11
5.
6
−3
.8
14
36
32
5_
at
Ro
ra
R
A
R
-r
el
at
ed
 o
rp
ha
n 
re
ce
pt
or
 α
21
.2
79
.6
−3
.8
14
39
34
8_
at
S1
00
a1
0
S1
00
 c
al
ci
um
-b
in
di
ng
 p
ro
te
in
 A
10
65
.2
24
4.
2
−3
.7
14
19
06
0_
at
G
zm
b
G
ra
nz
ym
e 
B
79
.2
29
5.
2
−3
.7
14
19
20
2_
at
C
st
7
C
ys
ta
tin
 F
15
2.
3
55
4.
8
−3
.6
14
19
57
3_
a_
at
Lg
al
s1
Le
ct
in
, g
al
ac
to
se
 b
in
di
ng
, s
ol
ub
le
 1
52
0.
8
18
53
.3
−3
.6
14
16
02
9_
at
Ti
eg
1
TG
F-
 β-
in
du
ci
bl
e 
ea
rly
 g
ro
w
th
 re
sp
on
se
 1
92
.8
32
2.
3
−3
.5
14
55
16
6_
at
Ar
l8
A
D
P 
rib
os
yl
at
io
n 
fa
ct
or
-li
ke
 8
14
0.
0
48
4.
2
−3
.5
14
26
20
8_
x_
at
Pl
ag
l1
Pl
ei
om
or
ph
ic
 a
de
no
m
a 
ge
ne
-li
ke
 1
94
.0
31
8.
2
−3
.4
14
16
95
8_
at
N
r1
d2
N
uc
le
ar
 re
ce
pt
or
 su
bf
am
ily
 1
, g
ro
up
 D
, m
em
be
r 2
39
.5
13
0.
9
−3
.3
14
49
31
0_
at
Pt
ge
r2
PG
ER
2
42
.4
13
8.
4
−3
.3
14
44
50
0_
at
Ah
sa
1
A
H
A
1,
 a
ct
iv
at
or
 o
f h
ea
t s
ho
ck
 9
0-
kD
a 
pr
ot
ei
n 
A
TP
as
e 
ho
m
ol
og
 1
50
.9
16
2.
9
−3
.2
14
17
93
5_
at
M
kr
n2
M
ak
or
in
, r
in
g 
fin
ge
r p
ro
te
in
, 2
24
3.
9
77
5.
2
−3
.2
J Immunol. Author manuscript; available in PMC 2011 April 26.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Getnet et al. Page 21
Pr
ob
e 
Se
t I
D
a
G
en
e 
Sy
m
bo
l
G
en
e 
T
itl
e
Pr
oH
A
 ×
 T
R
A
M
P
C
3-
H
A
Fo
ld
 C
ha
ng
e
14
48
37
0_
at
U
lk
1
U
nc
-5
1-
lik
e 
ki
na
se
 1
26
0.
0
81
4.
9
−3
.1
14
50
75
3_
at
N
kg
7
N
at
ur
al
 k
ill
er
 c
el
l g
ro
up
 7
 se
qu
en
ce
11
1.
4
34
6.
7
−3
.1
14
35
87
4_
at
Pr
ka
b2
Pr
ot
ei
n 
ki
na
se
, A
M
P-
ac
tiv
at
ed
, β
2 
no
nc
at
al
yt
ic
 su
bu
ni
t
10
4.
8
32
3.
6
−3
.1
14
49
23
5_
at
Tn
fs
f6
TN
F 
(li
ga
nd
) s
up
er
fa
m
ily
, m
em
be
r 6
79
.8
23
0.
8
−2
.9
14
19
09
1_
a_
at
An
xa
2
A
nn
ex
in
 A
2
34
5.
1
96
5.
4
−2
.8
14
19
83
8_
s_
at
St
k1
8
Se
rin
e/
th
re
on
in
e 
ki
na
se
 1
8
33
.6
93
.6
−2
.8
14
50
71
4_
at
O
az
in
O
rn
ith
in
e 
de
ca
rb
ox
yl
as
e 
an
tiz
ym
e 
in
hi
bi
to
r
96
.7
26
6.
8
−2
.8
14
28
39
3_
at
N
rn
1
N
eu
rit
in
 1
39
3.
1
10
73
.4
−2
.7
14
57
52
8_
at
Sl
c4
a7
So
lu
te
 c
ar
rie
r f
am
ily
 4
, s
od
iu
m
 b
ic
ar
bo
na
te
 c
ot
ra
ns
po
rte
r, 
m
em
be
r 7
48
.7
13
1.
0
−2
.7
14
21
96
3_
a_
at
C
dc
25
b
C
el
l d
iv
is
io
n 
cy
cl
e 
25
 h
om
ol
og
 B
97
.8
26
2.
8
−2
.7
14
27
62
9_
at
Pt
pr
j
Pr
ot
ei
n 
ty
ro
si
ne
 p
ho
sp
ha
ta
se
, r
ec
ep
to
r t
yp
e,
 J
17
.5
46
.8
−2
.7
14
56
12
6_
at
M
al
t1
M
uc
os
a-
as
so
ci
at
ed
 ly
m
ph
oi
d 
tis
su
e 
ly
m
ph
om
a 
tra
ns
lo
ca
tio
n 
ge
ne
 1
75
.2
20
0.
9
−2
.7
a I
D
, i
de
nt
ifi
ca
tio
n 
nu
m
be
r; 
PH
D
, p
la
nt
 h
om
eo
do
m
ai
n.
J Immunol. Author manuscript; available in PMC 2011 April 26.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Getnet et al. Page 22
Ta
bl
e 
III
G
en
es
 d
iff
er
en
tia
lly
 u
p-
re
gu
la
te
d 
by
 C
D
4 
T 
ce
lls
 e
xp
er
ie
nc
in
g 
A
g 
de
riv
ed
 fr
om
 tu
m
or
 (P
ro
H
A
 ×
 T
R
A
M
P)
 v
s v
iru
s (
V
ac
cH
A
)
Pr
ob
e 
Se
t I
D
a
G
en
e 
Sy
m
bo
l
G
en
e 
T
itl
e
Pr
oH
A
 ×
 T
R
A
M
P
V
ac
cH
A
Fo
ld
 C
ha
ng
e
14
56
95
6_
at
Zf
pn
1a
2
Zi
nc
 fi
ng
er
 p
ro
te
in
, s
ub
fa
m
ily
 1
A
, 2
85
9
10
5
8.
2
14
17
48
1_
at
Ra
m
p 
1
R
ec
ep
to
r (
ca
lc
ito
ni
n)
 a
ct
iv
ity
-m
od
ify
in
g 
pr
ot
ei
n 
1
47
0
63
7.
5
14
55
26
5_
a_
at
Rg
s1
6
R
eg
ul
at
or
 o
f G
-p
ro
te
in
 si
gn
al
in
g 
16
33
7
47
7.
2
14
28
83
4_
at
D
us
p4
D
ua
l-s
pe
ci
fic
ity
 p
ho
sp
ha
ta
se
 4
11
39
17
3
6.
6
14
36
75
9_
x_
at
C
nn
3
C
al
po
ni
n 
3,
 a
ci
di
c
23
2
44
5.
2
14
19
15
6_
at
So
x4
SR
Y
-b
ox
 c
on
ta
in
in
g 
ge
ne
 4
26
1
54
4.
8
14
50
82
6_
a_
at
Sa
a3
Se
ru
m
 a
m
yl
oi
d 
A
 3
13
70
28
6
4.
8
14
41
76
0_
at
Rp
s2
5
R
ib
os
om
al
 p
ro
te
in
 S
25
86
6
18
7
4.
6
14
16
51
4_
a_
at
Fs
cn
1
Fa
sc
in
 h
om
ol
og
 1
, a
ct
in
-b
un
dl
in
g 
pr
ot
ei
n 
(S
tr
on
gy
lo
ce
nt
ro
tu
s p
ur
pu
ra
tu
s)
61
1
13
6
4.
5
14
49
98
4_
at
C
xc
l2
C
he
m
ok
in
e 
(C
-X
-C
 m
ot
if)
 li
ga
nd
 2
20
8
47
4.
4
14
18
44
9_
at
La
d1
La
di
ni
n
54
2
12
5
4.
3
14
38
14
8_
at
G
m
1 
96
0
G
en
e 
m
od
el
 1
 9
60
52
12
4.
3
14
33
57
5_
at
So
x4
SR
Y
 b
ox
-c
on
ta
in
in
g 
ge
ne
 4
64
15
4.
2
14
22
89
2_
s_
at
H
2-
Ea
H
is
to
co
m
pa
tib
ili
ty
 2
, c
la
ss
 II
 A
g 
Eα
11
08
26
8
4.
1
14
34
49
9_
a_
at
Ld
h2
La
ct
at
e 
de
hy
dr
og
en
as
e 
2,
 B
 c
ha
in
18
6
46
4.
1
14
26
73
8_
at
D
gk
z
D
ia
cy
lg
ly
ce
ro
l k
in
as
e 
ζ
92
6
23
2
4.
0
14
28
32
9_
a_
at
W
dr
5 
6
W
D
 re
pe
at
 d
om
ai
n 
56
37
0
95
3.
9
14
23
54
7_
at
Ly
zs
Ly
so
zy
m
e
86
7
22
3
3.
9
14
38
37
0_
x_
at
D
os
D
ow
ns
tre
am
 o
f S
tk
11
43
0
11
1
3.
9
14
37
80
7_
x_
at
C
tn
na
1
C
at
en
in
 (c
ad
he
rin
-a
ss
oc
ia
te
d 
pr
ot
ei
n)
, α
1
35
0
92
3.
8
14
26
11
2_
a_
at
C
d7
2
C
D
72
 A
g
26
7
71
3.
8
14
52
54
3_
a_
at
Sc
gb
1a
1
Se
cr
et
og
lo
bi
n,
 fa
m
ily
 1
A
, m
em
be
r 1
10
1
27
3.
7
14
17
92
5_
at
C
cl
2 
2
C
he
m
ok
in
e 
(C
-C
 m
ot
if)
 li
ga
nd
 2
2
12
54
33
8
3.
7
14
16
71
4_
at
Ic
sb
p 
1
IF
N
 c
on
se
ns
us
 se
qu
en
ce
-b
in
di
ng
 p
ro
te
in
 1
61
7
16
6
3.
7
14
16
11
1_
at
C
d8
3
C
D
83
 A
g
44
9
12
1
3.
7
14
19
29
7_
at
H
2-
O
a
H
is
to
co
m
pa
tib
ili
ty
 2
, O
 re
gi
on
 a
lp
ha
 lo
cu
s
54
1
14
6
3.
7
14
21
03
8_
a_
at
K
cn
n4
Po
ta
ss
iu
m
 in
te
rm
ed
ia
te
/s
m
al
l c
on
du
ct
an
ce
 c
al
ci
um
-a
ct
iv
at
ed
 c
ha
nn
el
, s
ub
fa
m
ily
 N
, m
em
be
r 4
53
9
14
6
3.
7
14
56
70
0_
x_
at
M
ar
ck
s
M
yr
is
to
yl
at
ed
 a
la
ni
ne
-r
ic
h 
pr
ot
ei
n 
ki
na
se
 C
 su
bs
tra
te
22
0
60
3.
7
J Immunol. Author manuscript; available in PMC 2011 April 26.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Getnet et al. Page 23
Pr
ob
e 
Se
t I
D
a
G
en
e 
Sy
m
bo
l
G
en
e 
T
itl
e
Pr
oH
A
 ×
 T
R
A
M
P
V
ac
cH
A
Fo
ld
 C
ha
ng
e
14
21
07
3_
a_
at
Pt
ge
r4
PG
ER
 4
54
15
3.
7
14
36
95
9_
x_
at
N
el
f
N
as
al
 e
m
br
yo
ni
c 
LH
R
H
 fa
ct
or
12
88
35
1
3.
7
14
56
94
1_
at
Te
rt
Te
lo
m
er
as
e 
re
ve
rs
e 
tra
ns
cr
ip
ta
se
76
21
3.
6
14
37
27
0_
a_
at
Bs
f3
C
ar
di
ot
ro
ph
in
-li
ke
 c
yt
ok
in
e 
fa
ct
or
 1
27
8
78
3.
6
14
20
40
4_
at
C
d8
6
C
D
86
 A
g
47
4
13
5
3.
5
14
28
64
3_
at
M
ga
t5
M
an
no
si
de
 a
ce
ty
lg
lu
co
sa
m
in
yl
tra
ns
fe
ra
se
 5
26
3
75
3.
5
14
19
54
9_
at
Ar
g1
A
rg
in
as
e 
1,
 li
ve
r
68
20
3.
5
14
51
28
5_
at
Fu
s
Fu
si
on
, d
er
iv
ed
 fr
om
 t(
12
;1
6)
 m
al
ig
na
nt
 li
po
sa
rc
om
a 
(h
um
an
)
18
3
53
3.
5
14
32
46
6_
a_
at
Ap
oe
A
po
lip
op
ro
te
in
 E
73
21
3.
4
14
38
27
4_
at
Zf
pn
1a
4
Zi
nc
 fi
ng
er
 p
ro
te
in
, s
ub
fa
m
ily
 1
A
, 4
34
1
99
3.
4
14
19
08
3_
at
Tn
fs
f1
 1
TN
F 
(li
ga
nd
) s
up
er
fa
m
ily
, m
em
be
r 1
1
32
1
94
3.
4
14
35
29
0_
x_
at
H
2-
Aa
H
is
to
co
m
pa
tib
ili
ty
 2
, c
la
ss
 II
 A
g 
A
, α
13
07
38
4
3.
4
a I
D
, i
de
nt
ifi
ca
tio
n 
nu
m
be
r; 
PH
D
, p
la
nt
 h
om
eo
do
m
ai
n;
 R
A
B
, R
as
-r
el
at
ed
; R
A
R
, r
et
in
oi
c 
ac
id
 re
ce
pt
or
; R
as
, r
at
 sa
rc
om
a.
J Immunol. Author manuscript; available in PMC 2011 April 26.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Getnet et al. Page 24
Ta
bl
e 
IV
G
en
es
 d
iff
er
en
tia
lly
 d
ow
n-
re
gu
la
te
d 
by
 C
D
4 
T 
ce
lls
 e
xp
er
ie
nc
in
g 
A
g 
de
riv
ed
 fr
om
 tu
m
or
 (P
ro
H
A
 ×
 T
R
A
M
P)
 v
s v
iru
s (
V
ac
cH
A
)
Pr
ob
e 
Se
t I
D
a
G
en
e 
Sy
m
bo
l
G
en
e 
T
itl
e
Pr
oH
A
 ×
 T
R
A
M
P
V
ac
cH
A
Fo
ld
 C
ha
ng
e
14
58
94
7_
at
Fa
nc
c
Fa
nc
on
i a
ne
m
ia
, c
om
pl
em
en
ta
tio
n 
gr
ou
p 
C
42
0
78
7
−1
.9
14
44
67
6_
at
C
tc
f
C
C
C
TC
-b
in
di
ng
 fa
ct
or
60
11
2
−1
.9
14
41
66
9_
at
C
en
tb
2
C
en
ta
ur
in
, β
2
12
5
23
3
−1
.9
14
47
90
3_
x_
at
Ap
1s
2
A
da
pt
or
-r
el
at
ed
 p
ro
te
in
 c
om
pl
ex
 1
, σ
2 
su
bu
ni
t
26
3
49
3
−1
.9
14
59
73
6_
at
St
k 
10
Se
rin
e/
th
re
on
in
e 
ki
na
se
 1
0
13
4
25
0
−1
.9
14
38
68
3_
at
W
as
f2
W
A
S 
pr
ot
ei
n 
fa
m
ily
, m
em
be
r 2
12
5
23
3
−1
.9
14
45
33
7_
at
D
na
jc
13
D
na
J (
H
sp
40
) h
om
ol
og
, s
ub
fa
m
ily
 C
, m
em
be
r 1
3
13
7
25
5
−1
.9
14
23
72
7_
at
C
ni
h
C
or
ni
ch
on
 h
om
ol
og
26
0
48
3
−1
.9
14
45
92
8_
at
M
ar
ch
6
M
em
br
an
e-
as
so
ci
at
ed
 ri
ng
 fi
ng
er
 (C
3H
C
 4
) 6
14
0
26
1
−1
.9
14
55
88
6_
at
C
bl
C
as
ita
s B
-li
ne
ag
e 
ly
m
ph
om
a
44
8
83
3
−1
.9
14
40
72
9_
at
Ep
s1
5
Ep
id
er
m
al
 g
ro
w
th
 fa
ct
or
 re
ce
pt
or
 p
at
hw
ay
 su
bs
tra
te
 1
5
19
36
−1
.9
14
43
48
0_
at
Ra
ss
f3
R
as
 a
ss
oc
ia
tio
n 
(R
al
G
D
S/
A
F-
6)
 d
om
ai
n 
fa
m
ily
 3
15
9
29
5
−1
.9
14
26
55
9_
at
Sb
no
1
Sn
o,
 st
ra
w
be
rr
y 
no
tc
h 
ho
m
ol
og
 1
63
5
11
77
−1
.9
14
48
88
5_
at
Ra
p 
2b
R
A
P2
B
, m
em
be
r o
f R
A
S 
on
co
ge
ne
 fa
m
ily
23
0
42
6
−1
.9
14
23
42
3_
at
Pd
ia
3
Pr
ot
ei
n 
di
su
lfi
de
 is
om
er
as
e-
as
so
ci
at
ed
 3
63
11
6
−1
.9
14
17
27
0_
at
W
dr
12
W
D
 re
pe
at
 d
om
ai
n 
12
39
72
−1
.9
14
22
53
3_
at
C
yp
51
C
yt
oc
hr
om
e 
P4
50
, f
am
ily
 5
1
26
49
−1
.9
14
15
83
8_
at
Td
e2
Tu
m
or
 d
iff
er
en
tia
lly
 e
xp
re
ss
ed
 2
12
4
23
0
−1
.8
14
19
75
8_
at
Ab
cb
 1
a
A
TP
-b
in
di
ng
 c
as
se
tte
, s
ub
fa
m
ily
 B
 (M
D
R
/T
A
P)
, m
em
be
r 1
A
22
40
−1
.8
14
20
02
1_
s_
at
Su
z1
2
Su
pp
re
ss
or
 o
f z
es
te
 1
2 
ho
m
ol
og
32
8
60
4
−1
.8
14
20
49
7_
a_
at
C
eb
pz
C
C
A
A
T/
en
ha
nc
er
 b
in
di
ng
 p
ro
te
in
 z
et
a
89
16
4
−1
.8
14
19
49
7_
at
C
dk
n1
 b
C
yc
lin
-d
ep
en
de
nt
 k
in
as
e 
in
hi
bi
to
r 1
B
36
65
−1
.8
14
23
81
9_
s_
at
Ar
l6
ip
1
A
D
P 
rib
os
yl
at
io
n 
fa
ct
or
-li
ke
 6
-in
te
ra
ct
in
g 
pr
ot
ei
n 
1
80
5
14
80
−1
.8
14
50
09
3_
s_
at
Zb
tb
7a
Zi
nc
 fi
ng
er
 a
nd
 B
TB
 d
om
ai
n 
co
nt
ai
ni
ng
 7
a
30
56
−1
.8
14
59
63
5_
at
D
lg
h1
D
is
cs
, l
ar
ge
 h
om
ol
og
 1
55
10
1
−1
.8
14
53
36
1_
at
H
el
ls
H
el
ic
as
e,
 ly
m
ph
oi
d 
sp
ec
ifi
c
18
33
−1
.8
14
17
37
1_
at
Pe
li1
Pe
lli
no
 1
52
8
96
8
−1
.8
14
46
20
5_
at
N
fy
c
N
uc
le
ar
 tr
an
sc
rip
tio
n 
fa
ct
or
-Y
γ
89
16
2
−1
.8
J Immunol. Author manuscript; available in PMC 2011 April 26.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Getnet et al. Page 25
Pr
ob
e 
Se
t I
D
a
G
en
e 
Sy
m
bo
l
G
en
e 
T
itl
e
Pr
oH
A
 ×
 T
R
A
M
P
V
ac
cH
A
Fo
ld
 C
ha
ng
e
14
29
52
5_
s_
at
M
yo
1f
M
yo
si
n 
IF
33
61
−1
.8
14
48
33
9_
at
Tm
em
30
 a
Tr
an
sm
em
br
an
e 
pr
ot
ei
n 
30
A
66
12
1
−1
.8
14
41
46
0_
at
Fg
fr
1o
p 
2
FG
FR
1 
on
co
ge
ne
 p
ar
tn
er
 2
71
13
0
−1
.8
14
59
45
7_
at
C
am
k2
d
C
al
ci
um
/c
al
m
od
ul
in
-d
ep
en
de
nt
 p
ro
te
in
 k
in
as
e 
II
, d
el
ta
17
0
31
0
−1
.8
14
31
19
7_
at
Ar
l6
ip
2
A
D
P 
rib
os
yl
at
io
n 
fa
ct
or
-li
ke
 6
-in
te
ra
ct
in
g 
pr
ot
ei
n 
2
82
14
9
−1
.8
14
22
76
9_
at
Sy
nc
ri
p
Sy
na
pt
ot
ag
m
in
 b
in
di
ng
, c
yt
op
la
sm
ic
 R
N
A
 in
te
ra
ct
in
g 
pr
ot
ei
n
15
27
−1
.8
14
34
03
9_
at
Ap
pb
p2
A
m
yl
oi
d 
β p
re
cu
rs
or
 p
ro
te
in
 (c
yt
op
la
sm
ic
 ta
il)
-b
in
di
ng
 p
ro
te
in
 2
22
40
−1
.8
14
52
11
5_
a_
at
Pl
k4
Po
lo
-li
ke
 k
in
as
e 
4
17
31
−1
.8
14
49
48
0_
at
Sa
p 
18
Si
n 
3-
as
so
ci
at
ed
 p
ol
yp
ep
tid
e 
18
46
84
−1
.8
14
24
44
3_
at
Tm
6s
f1
Tr
an
sm
em
br
an
e 
6 
su
pe
rf
am
ily
 m
em
be
r 1
12
22
−1
.8
14
41
31
9_
at
Rb
m
5
R
N
A
-b
in
di
ng
 m
ot
if 
pr
ot
ei
n 
5
52
95
−1
.8
14
38
06
4_
at
N
se
p 
1
N
uc
le
as
e-
se
ns
iti
ve
 e
le
m
en
t b
in
di
ng
 p
ro
te
in
 1
26
2
47
8
−1
.8
14
37
88
4_
at
Ar
l8
A
D
P 
rib
os
yl
at
io
n 
fa
ct
or
-li
ke
 8
71
12
9
−1
.8
a I
D
, i
de
nt
ifi
ca
tio
n 
nu
m
be
r; 
M
D
R
, m
ul
tid
ru
g 
re
si
st
an
t; 
FG
FR
, f
ib
ro
bl
as
t g
ro
w
th
 fa
ct
or
 re
ce
pt
or
; W
A
S,
 W
is
ko
tt-
A
ld
ric
h 
sy
nd
ro
m
e;
 R
as
, r
at
 sa
rc
om
a;
 B
TB
, b
ric
-a
-b
ra
c,
 tr
am
tra
ck
, a
nd
 b
ro
ad
 c
om
pl
ex
.
J Immunol. Author manuscript; available in PMC 2011 April 26.
